Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Portfolio
Technologies
Licensing Opportunities

Investor Relations

View Investor Relations

Stock Snapshot

LGND
NASDAQ
Day Range
52-Week Range
Volume

Latest News

Ligand Announces First Quarter 2016 Earnings Reporting Date and Participation in Four Upcoming Investor Conferences

Read More

Revolade® Approved in EU as First in Class Therapy for Children Aged 1 Year and Above with Chronic ITP

Read More

Ligand Enters Into OmniAb® Platform License Agreement With ABBA Therapeutics

Read More

Social